The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Evolving treatment landscape in MF: JAK inhibitors, combination therapy, and novel agents
Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the evolving treatment landscape in myelofibrosis (MF), emphasizing that allogeneic stem cell transplantation (alloSCT) remains the only curative option for eligible patients. Dr Pemmaraju highlights ongoing studies exploring strategies beyond the four approved JAK inhibitors, including combination approaches, add-on therapies, and novel agents that may complement or move beyond JAK inhibitor-based treatment. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, so here at SOHO 2026 in Houston, I was able to lead and chair a session called Meet the Professors or MTP session on myelofibrosis and MPNs. And my particular talk was on individualizing or personalizing that treatment. It’s actually quite remarkable. Now we’ve gone from just really one paradigm to JAK inhibitors to multiple approaches. One that I stressed is that allogeneic stem cell transplant still remains the only curative approach for patients with intermediate to high-risk MF...
Yeah, so here at SOHO 2026 in Houston, I was able to lead and chair a session called Meet the Professors or MTP session on myelofibrosis and MPNs. And my particular talk was on individualizing or personalizing that treatment. It’s actually quite remarkable. Now we’ve gone from just really one paradigm to JAK inhibitors to multiple approaches. One that I stressed is that allogeneic stem cell transplant still remains the only curative approach for patients with intermediate to high-risk MF. That’s important. So not necessarily a drug or a drug class, but allo transplant. As allo transplant becomes safer and more available to more patients, in more centers around the world, that’s an important concept. Number two, targeted therapies, all are investigational. Beyond the four approved JAK inhibitors and how to sequence them, now there are clinical trials where we either combine a novel agent with the JAK inhibitor, one. Two, add in a suboptimal response or then add in a second drug. Or three, from the beginning, you use a combination of a JAK inhibitor and a novel agent. So we talked about that. And then finally, the exciting new era of completely novel agents beyond JAK inhibitors. So those are for patients who’ve already been through a JAK inhibitor or even the prospect of making two drugs that are not JAK inhibitors together, so-called novel, novel combination. So anyway, we did talk about all that. So separating out standard of care, the four approved JAK inhibitors versus then investigational clinical approaches, which aim to either combine, add on, or go beyond JAK.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
